Market Overview

UPDATE: Citigroup Initiates Coverage on The Medicines Company with Neutral Rating, $27 PT

Share:
Related MDCO
Why Is The Medicines Company Stock Falling? This Analyst May Have An Answer
Eagle Pharma Has 'Several Upcoming Catalysts' And Is A Buy, RBC Says
The Medicines Co. Down on Wider-than-Expected Loss in Q2 - Analyst Blog (Zacks)

In a report published Friday, Citigroup initiated coverage on The Medicines Company (NASDAQ: MDCO) with a Neutral rating and $27.00 price target.

Citigroup noted, “We are cautious on the ability of MDCO's pipeline to replace the >90% of total revenues represented by Angiomax before the drug's 2019 loss of exclusivity. Based on our research and physician checks, we question whether the cumulative opportunities for Cleviprex, cangrelor, and oritavancin would be sufficient to offset the revenue gap, even assuming cangrelor and oritavancin are ultimately approved. In the interim, remaining patent litigation and pivotal readouts from Angiomax's competitors present risks to nearer-term cash flows. We are initiating with a Neutral/High Risk rating and $27 price target.”

The Medicines Company closed on Thursday at $23.07.

Latest Ratings for MDCO

DateFirmActionFromTo
Jul 2015Mizuho SecuritiesUpgradesNeutralBuy
May 2015Leerink SwannMaintainsOutperform
May 2015JP MorganMaintainsOverweight

View More Analyst Ratings for MDCO
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Initiation Analyst Ratings

 

Related Articles (MDCO)

Get Benzinga's Newsletters